Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland

Pharmacotherapy

Volumn 36, Issue 5, 2016, Pages 472-481

  Stawowczyk, Ewa ^a   Kawalec, Paweł ^b   Pilc, Andrzej ^c  

^a Linde Gaz Polska Sp z oo   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Cost utility; Economic analysis; Inflammatory bowel disorder; Infliximab; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; PLACEBO; PREDNISOLONE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLAND; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REMISSION; STANDARDIZATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; COLITIS, ULCERATIVE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; MARKOV CHAIN; STATISTICS AND NUMERICAL DATA;

COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INFLIXIMAB; MARKOV CHAINS; POLAND; QUALITY-ADJUSTED LIFE YEARS;

EID: 84964754656     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1742     Document Type: Article

References (18)

1. Baumgart DC, Sandborn WJ,. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-57.
2. Feagan BG, Reinisch W, Rutgeerts P, et al., The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802.
3. Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
4. Ordás I, Eckmann L, Talamini M, et al., Ulcerative colitis. Lancet 2012; 380: 1606-19.
5. Farrell TJ, Peppercorn MA,. Ulcerative colitis. Lancet 2002; 359: 331-40.
6. Rutgeerts P, Sandborn WJ, Feagan BG, et al., Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
7. Croft A, Walsh A, Doecke J, et al., Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013; 38: 294-302.
8. Agency for Health Technology Assessment. Polish Guidelines for Health Technology Assessment. 2009. Available from www.aotm.gov.pl. Accessed December 2015.
9. Summary of Product Characteristic Remsima. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002576/WC500150871.pdf. Accessed March 2016.
10. Arseneau KO, Sultan S, Provenzale DT, et al., Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol 2006; 4: 1135-42.
11. Sandborn WJ, van Assche G, Reinish W, et al., Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
12. Sandborn WJ, Rutgeerts P, Feagan BG, et al., Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-60.
13. Arai K, Koganei K, Kimura H, et al., Incidence and outcome of complications following restorative proctocolectomy. Am J Surg 2005; 190: 39-42.
14. Woehl A, Hawthorne B, Morgan C, et al., The epidemiology and healthcare resource use in patients with Crohn's disease: a population based UK study. Value Health 2007; 10: A355.
15. Fazio VW, Ziv Y, Church JM, et al., Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995; 222 (2): 120-7.
16. Summary of Product Characteristic Humira. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000481/WC500050870.pdf. Accessed March 2016.
17. Evertsz' FB, Nieuwkerk PT, Stokkers PCF, et al., The patient simple clinical colitis activity index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers. J Crohns Colitis 2013; 7: 890-900.
18. Xie F, Blackhouse G, Assasi N, et al., Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc 2009; 7: 20.